Key Financials Snapshot

TTM · Standalone · ₹ in Cr
Market Cap
₹99 Cr.
Stock P/E
254.2
P/B
4.1
Current Price
₹49.8
Book Value
₹ 12.1
Face Value
10
52W High
₹52
52W Low
₹ 16.7
Dividend Yield
0%

Veerhealth Care Overview

Business

Veerhealth Care Ltd. is an India-based company primarily engaged in the manufacturing, marketing, and distribution of a diverse range of healthcare and wellness products. Its core business revolves around Ayurvedic products, herbal products, nutraceuticals, and cosmeceuticals. The company develops, produces, and sells these products under its own brands. Additionally, it provides third-party contract manufacturing services to other companies in the healthcare and personal care segments. Veerhealth Care Ltd. generates revenue through direct sales of its manufactured goods to distributors, retailers, and potentially online channels, as well as through manufacturing fees for contract production.

Revenue Mix

Veerhealth Care Ltd. generally does not provide a detailed breakdown of revenue by specific product categories (e.g., Ayurvedic vs. Nutraceuticals) or by own brands versus contract manufacturing in its public filings. The primary revenue stream is derived from the "Sale of Products." Based on their operations, revenue is broadly generated from:

Finished Goods Sales: Comprising sales of their proprietary branded products and products manufactured under contract for other entities.

(Specific percentage contributions are not readily available in public documents for this company.)

Industry

The company operates within the highly competitive and growing Indian healthcare and wellness industry, specifically focusing on the Ayurvedic, herbal, nutraceutical, and cosmeceutical sub-sectors. This market is characterized by increasing consumer demand for natural and preventive health solutions.

The industry structure is fragmented, comprising large, established domestic and international players (e.g., Dabur, Himalaya, Patanjali) with strong brand recognition and extensive distribution networks, alongside numerous regional and unorganized manufacturers.

Veerhealth Care Ltd. is positioned as a relatively smaller player in this landscape, operating on the NSE Emerge platform for SMEs. Its positioning likely relies on a focused product portfolio, potential regional distribution strengths, and its capabilities as a contract manufacturer.

MOAT

As an SME in a highly competitive market, Veerhealth Care Ltd. likely possesses limited strong, durable competitive advantages.

Mild Advantages:

Manufacturing Expertise: Capabilities and certifications for producing a range of Ayurvedic, herbal, and nutraceutical formulations could provide a slight advantage in attracting contract manufacturing clients.

Product Diversification: Offering a broad basket of products across different wellness categories may appeal to a wider customer base.

Distribution Relationships: Established relationships with distributors in specific regions might offer some market penetration, but this is often localized.

Limited/No Strong Moats: The company is unlikely to have significant brand equity, economies of scale, proprietary technology, or high switching costs that would act as strong competitive moats against larger industry players.

Growth Drivers

Expanding Health & Wellness Market: The overall growth in consumer awareness and preference for natural, herbal, and preventive healthcare products in India.

Rising Nutraceutical Demand: Increasing adoption of dietary supplements and functional foods driven by health consciousness and lifestyle changes.

Digital Penetration & E-commerce: Leveraging online sales channels to expand market reach beyond traditional distribution networks.

Product Innovation & Portfolio Expansion: Introducing new and niche products to cater to evolving consumer preferences and health trends.

Growth in Contract Manufacturing: Opportunities to secure more private label or contract manufacturing orders from other wellness brands.

Risks

Intense Competition: Significant competition from larger, well-funded national players with strong brands and marketing budgets, as well as numerous unorganized local players.

Regulatory Scrutiny: Strict and evolving regulatory frameworks for Ayurvedic, herbal, nutraceuticals, and cosmeceuticals (e.g., AYUSH, FSSAI) can impact product development, approvals, and marketing claims.

Raw Material Volatility: Dependence on the availability and fluctuating prices of natural and herbal raw materials.

Product Quality & Reputational Risk: Any quality issues, adverse publicity, or lack of efficacy could severely damage brand trust and sales.

Distribution Network Challenges: Difficulties in expanding and managing an effective distribution network, especially for an SME aiming for broader reach.

Funding Constraints: As an SME, access to significant capital for large-scale expansion, R&D, and marketing can be limited.

Management & Ownership

Veerhealth Care Ltd. is a promoter-driven company. Mr. Virendra Kumar Singh serves as a key promoter and the Managing Director, indicating significant promoter involvement in daily operations and strategic direction. Promoter holding typically represents a substantial portion of the company's equity, ensuring tight control over the business. Management quality, typical for SMEs, is often characterized by hands-on operational focus, with growth and governance subject to the oversight of the promoter group and compliance with SME listing requirements. The remaining ownership is held by the public and other non-promoter shareholders.

Outlook

Veerhealth Care Ltd. operates in a sector with favorable tailwinds driven by rising health awareness and consumer preference for natural solutions in India. Its diversified product range across Ayurvedic, herbal, nutraceuticals, and cosmeceuticals, along with its contract manufacturing capabilities, provides multiple avenues for potential growth. However, as an SME, the company faces formidable challenges from a highly competitive market dominated by larger, established players with superior brand recognition and financial muscle. The outlook is cautiously optimistic, dependent on the company's ability to effectively execute its growth strategies, differentiate its products, navigate regulatory complexities, maintain stringent quality standards, and successfully expand its market presence within its operational constraints.

Veerhealth Care Share Price

Live · BSE / NSE · Inception: 1992
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Standalone · annual

Veerhealth Care Quarterly Results

#(Fig in Cr.) Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 3 2 5 4 6 4 4 7 17 25
Other Income 0 0 0 0 0 1 0 -0 0 0
Total Income 4 2 5 4 6 5 4 7 17 25
Total Expenditure 3 2 5 4 6 5 3 6 16 23
Operating Profit 0 0 1 0 0 1 1 1 1 2
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 -0 0
Profit Before Tax 0 0 0 0 -0 0 0 0 0 1
Provision for Tax 1 0 0 0 -0 0 0 0 1 0
Profit After Tax -1 0 0 0 -0 0 0 0 -0 1
Adjustments 0 -0 0 0 0 0 0 0 0 0
Profit After Adjustments -1 0 0 0 -0 0 0 0 -0 1
Adjusted Earnings Per Share -0.3 0.1 0.1 0 -0.1 0.1 0.1 0.2 -0.2 0.6

Veerhealth Care Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 1 2 2 5 6 12 11 10 13 13 17 53
Other Income 0 0 1 1 0 0 1 2 1 1 1 0
Total Income 2 3 3 6 6 12 12 11 15 15 18 53
Total Expenditure 1 2 2 5 6 11 11 10 13 13 16 48
Operating Profit 0 0 0 1 1 1 1 1 2 2 2 5
Interest 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 1 1 1 1 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 0 0 0 0 0 1 1 0 1 1 1 1
Provision for Tax 0 0 0 0 0 0 0 0 -0 1 0 1
Profit After Tax 0 0 0 0 0 0 0 -0 2 0 0 1
Adjustments 0 0 0 0 0 0 0 0 -0 0 0 0
Profit After Adjustments 0 0 0 0 0 0 0 -0 2 0 0 1
Adjusted Earnings Per Share 0 0 0 0.1 0.1 0.2 0.3 -0.1 0.8 0.2 0.2 0.7

Veerhealth Care Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 13 13 13 13 13 14 14 14 21 22 22
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 1 1 0 0 0 2 1 0 0 0 4
Other Non-Current Liabilities 0 0 0 0 0 1 2 4 3 4 4
Total Current Liabilities 1 1 -0 1 3 1 2 2 1 3 4
Total Liabilities 14 14 13 15 16 18 19 20 25 28 34
Fixed Assets 2 3 3 6 5 9 9 11 12 12 20
Other Non-Current Assets 4 5 3 2 8 2 2 3 3 3 3
Total Current Assets 8 7 8 7 3 6 7 6 10 13 11
Total Assets 14 14 13 15 16 18 19 20 25 28 34

Veerhealth Care Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents -0 0 0 0 0 0 0 0 0 4 0
Cash Flow from Operating Activities -4 -0 2 2 2 -0 1 2 -1 3 -0
Cash Flow from Investing Activities 4 -0 -0 -3 -2 -2 -0 -1 -2 -0 -8
Cash Flow from Financing Activities 0 0 -1 1 0 2 -1 -0 6 -6 10
Net Cash Inflow / Outflow 0 -0 -0 0 0 -0 0 0 3 -3 1
Closing Cash & Cash Equivalent 0 0 0 0 0 0 0 0 4 0 1

Veerhealth Care Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0.04 0.01 0.02 0.1 0.11 0.23 0.27 -0.05 0.79 0.2 0.2
CEPS(Rs) 0.12 0.15 0.18 0.3 0.34 0.46 0.61 0.32 1.1 0.56 0.65
DPS(Rs) 0 0 0 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) 9.21 9.24 9.27 9.45 9.58 9.92 10.13 10.06 10.72 10.92 11.11
Core EBITDA Margin(%) -12.17 -1 -18.88 -2.4 7.37 5.79 -0.59 -8.62 3.7 4.62 2.76
EBIT Margin(%) 16.1 7.21 6.89 6.22 6.9 7.14 7.52 3.35 8.42 9.75 4.63
Pre Tax Margin(%) 11.87 1.09 1.63 4.85 6.32 5.52 5.45 2.47 8.41 9.69 3.05
PAT Margin (%) 4.27 0.41 1.18 2.65 2.64 2.71 3.58 -0.76 11.92 3.07 2.35
Cash Profit Margin (%) 12.84 9.87 12.99 7.97 7.99 5.47 8.01 4.68 16.6 8.45 7.79
ROA(%) 0.42 0.06 0.17 0.99 1.02 1.86 2.07 -0.38 6.97 1.52 1.26
ROE(%) 0.45 0.07 0.18 1.06 1.2 2.35 2.73 -0.53 8.94 1.88 1.78
ROCE(%) 1.62 1.13 1 2.38 2.89 5.5 4.97 2.17 6.32 5.96 3.15
Receivable days 138.36 152.37 142.08 53.93 50.68 26.13 42.78 58.5 46.47 79.49 78.02
Inventory Days 76.45 133.21 252.5 87.4 54.32 32.23 49.91 71.8 65.03 55.23 42.05
Payable days 49.45 37.33 46.6 20.05 84.79 55.82 42.57 85.29 56.81 54.17 76.44
PER(x) 292.99 1111.05 368.2 63.23 32.87 13.83 13.9 0 12.67 102.22 62.54
Price/Book(x) 1.3 0.76 0.65 0.66 0.39 0.32 0.38 0.57 0.94 1.9 1.1
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 13.21 5.07 4.26 1.9 1 0.59 0.65 0.78 1.24 3.12 1.69
EV/Core EBITDA(x) 53.45 29.7 22.7 16.44 8.13 5.92 5.46 8.88 9.45 20.62 16.8
Net Sales Growth(%) -55.52 59.68 -9.61 169.67 15.77 95.97 -9.79 -9.01 37.89 -0.38 26.07
EBIT Growth(%) 452.06 -26.89 -15.45 142.82 28.46 102.71 -5.02 -59.42 246.51 15.27 -40.13
PAT Growth(%) 121.01 -84.51 157.95 503.96 15.39 101.2 19.13 -119.41 2249.46 -74.34 -3.6
EPS Growth(%) 121.01 -84.51 157.67 504.59 15.4 101.2 19.15 -119.4 1590.66 -74.34 -3.6
Debt/Equity(x) 0.08 0.08 -0.01 0.09 0.07 0.18 0.12 0 0 0 0.22
Current Ratio(x) 16.4 12.73 -22.94 5.69 1.12 4.13 4.34 2.53 10.61 4.85 3.06
Quick Ratio(x) 15.49 10.62 -18.5 4.91 0.8 3.31 3.28 1.67 7.94 4.35 2.37
Interest Cover(x) 3.8 1.18 1.31 4.54 11.97 4.4 3.64 3.79 860.15 169.61 2.92
Total Debt/Mcap(x) 0.06 0.11 -0.02 0.14 0.18 0.56 0.33 0 0 0 0.2

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +31% +19% +7% +33%
Operating Profit CAGR 0% +26% +15% —
PAT CAGR — — — —
Share Price CAGR +176% +38% +56% +20%
ROE Average +2% +4% +3% +2%
ROCE Average +3% +5% +5% +3%

Veerhealth Care Shareholding Pattern

Latest · Jun 2026
100% held
Promoters 31.91 %
FII 0 %
DII (MF + Insurance) 0 %
Public (retail) 68.09 %
# Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Promoter 30.4130.4130.4130.4131.531.531.531.531.531.91
FII 0000000000
DII 0000000000
Public 69.5969.5969.5969.5968.568.568.568.568.568.09
Others 0000000000
Total 100100100100100100100100100100

Veerhealth Care Peer Comparison

Veerhealth Care Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Veerhealth Care Pros & Cons

Pros

  • Company is almost debt free.

Cons

  • Promoter holding is low: 31.91%.
  • Company has a low return on equity of 4% over the last 3 years.
  • Debtor days have increased from 54.17 to 76.44days.
  • Stock is trading at 4.1 times its book value.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp